Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban

Stroke patients can recover upon intravenous thrombolysis but remain impaired in lacking recanalization. We sought to investigate the clinical effect of systemic thrombolysis with an intravenous bolus of 20 mg recombinant tissue plasminogen activator (rtPA) and an infusion of body-weight adjusted ti...

Full description

Bibliographic Details
Main Authors: Rudiger J. Seitz, Judith Sukiennik, Mario Siebler
Format: Article
Language:English
Published: MDPI AG 2012-09-01
Series:Neurology International
Subjects:
Online Access:http://www.pagepress.org/journals/index.php/ni/article/view/3665
id doaj-c1becf5edc4845b99a02a19d9c8611a0
record_format Article
spelling doaj-c1becf5edc4845b99a02a19d9c8611a02021-01-02T13:33:29ZengMDPI AGNeurology International2035-83852035-83772012-09-0142e9e910.4081/ni.2012.e92262Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofibanRudiger J. Seitz0Judith Sukiennik1Mario Siebler2Department of Neurology, University Hospital Düsseldorf, Biomedical Research Centre, Heinrich-Heine University Düsseldorf, Germany; Florey Neuroscience Institutes, Melbourne, AustraliaDepartment of Neurology, University Hospital DüsseldorfDepartment of Neurology, University Hospital Düsseldorf; Department of Neurology, Mediclin Fachklinik Rhein Ruhr, EssenStroke patients can recover upon intravenous thrombolysis but remain impaired in lacking recanalization. We sought to investigate the clinical effect of systemic thrombolysis with an intravenous bolus of 20 mg recombinant tissue plasminogen activator (rtPA) and an infusion of body-weight adjusted tirofiban for 48 hours in acute stroke. This prospective, open label study, included 192 patients (68±13 years, 50% males) treated between 1 January 2005 and 31 December 2007. The neurological deficit was assessed with the National Institutes of Health stroke scale (NIHSS). Follow-up was performed using a telephone interview of modified Rankin Scale (mRS) and Barthel index. The site of cerebral artery occlusion was determined by computed tomography or magnetic resonance angiography. Data were analyzed by descriptive statistics and multiple regression analyses. Eighty-one percent of the patients had an infarct in the middle cerebral artery (MCA) territory and were severely affected with a median NIHSS of 10. During treatment on the Stroke Unit the patients improved (P<0.0001) except for patients who deceased due to malignant infarction (n=10) or cerebral haemorrhage (n=6); 18 percent deceased within 100 days which was predicted by older age (76 + 10 years, P<0.05) and more severe affection on admission (P<0.0001). Also, these patients more frequently had atrial fibrillation (P<0.03) than the surviving patients. The surviving patients had more frequently distal MCA occlusions and improved further (P<0.0001). At follow-up 48% of the patients had a mRS of 0 and 1. Similarly to intravenous thrombolysis with body-weight adjusted rtPA, poor prognosis was predicted by higher age, more severe neurological deficit at stroke admission, and a proximal MCA occlusion. Half of the surviving patients improved to no or minimal impairment.http://www.pagepress.org/journals/index.php/ni/article/view/3665brain infarct, stroke, thrombolysis, tirofiban, impairment
collection DOAJ
language English
format Article
sources DOAJ
author Rudiger J. Seitz
Judith Sukiennik
Mario Siebler
spellingShingle Rudiger J. Seitz
Judith Sukiennik
Mario Siebler
Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
Neurology International
brain infarct, stroke, thrombolysis, tirofiban, impairment
author_facet Rudiger J. Seitz
Judith Sukiennik
Mario Siebler
author_sort Rudiger J. Seitz
title Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
title_short Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
title_full Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
title_fullStr Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
title_full_unstemmed Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
title_sort outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
publisher MDPI AG
series Neurology International
issn 2035-8385
2035-8377
publishDate 2012-09-01
description Stroke patients can recover upon intravenous thrombolysis but remain impaired in lacking recanalization. We sought to investigate the clinical effect of systemic thrombolysis with an intravenous bolus of 20 mg recombinant tissue plasminogen activator (rtPA) and an infusion of body-weight adjusted tirofiban for 48 hours in acute stroke. This prospective, open label study, included 192 patients (68±13 years, 50% males) treated between 1 January 2005 and 31 December 2007. The neurological deficit was assessed with the National Institutes of Health stroke scale (NIHSS). Follow-up was performed using a telephone interview of modified Rankin Scale (mRS) and Barthel index. The site of cerebral artery occlusion was determined by computed tomography or magnetic resonance angiography. Data were analyzed by descriptive statistics and multiple regression analyses. Eighty-one percent of the patients had an infarct in the middle cerebral artery (MCA) territory and were severely affected with a median NIHSS of 10. During treatment on the Stroke Unit the patients improved (P<0.0001) except for patients who deceased due to malignant infarction (n=10) or cerebral haemorrhage (n=6); 18 percent deceased within 100 days which was predicted by older age (76 + 10 years, P<0.05) and more severe affection on admission (P<0.0001). Also, these patients more frequently had atrial fibrillation (P<0.03) than the surviving patients. The surviving patients had more frequently distal MCA occlusions and improved further (P<0.0001). At follow-up 48% of the patients had a mRS of 0 and 1. Similarly to intravenous thrombolysis with body-weight adjusted rtPA, poor prognosis was predicted by higher age, more severe neurological deficit at stroke admission, and a proximal MCA occlusion. Half of the surviving patients improved to no or minimal impairment.
topic brain infarct, stroke, thrombolysis, tirofiban, impairment
url http://www.pagepress.org/journals/index.php/ni/article/view/3665
work_keys_str_mv AT rudigerjseitz outcomeaftersystemicthrombolysisispredictedbyageandstrokeseverityanopenlabelexperiencewithrecombinanttissueplasminogenactivatorandtirofiban
AT judithsukiennik outcomeaftersystemicthrombolysisispredictedbyageandstrokeseverityanopenlabelexperiencewithrecombinanttissueplasminogenactivatorandtirofiban
AT mariosiebler outcomeaftersystemicthrombolysisispredictedbyageandstrokeseverityanopenlabelexperiencewithrecombinanttissueplasminogenactivatorandtirofiban
_version_ 1724353884624781312